 BOSTON, April 08, 2021 GLOBE NEWSWIRE -- Inozyme Pharma, Inc. Nasdaq: INZY, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset ABCC6 and ENPP1 deficiency study will be presented at the American College of Medical Genetics and Genomics ACMG Annual Clinical Genetics Meeting taking place April 13-16, 2021. 